Assembly Biosciences, Inc. Deferred Income Tax Expense (Benefit)
Assembly Biosciences, Inc. (ASMB) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2025-03-20
- Assembly Biosciences, Inc. deferred income tax expense (benefit) for the quarter ending 2020-12-31 was $0.00.
- Assembly Biosciences, Inc. deferred income tax expense (benefit) for the quarter ending 2020-09-30 was $0.00.
- Assembly Biosciences, Inc. deferred income tax expense (benefit) for the quarter ending 2020-06-30 was $0.00.
- Assembly Biosciences, Inc. deferred income tax expense (benefit) for the quarter ending 2020-03-31 was $0.00.
- Assembly Biosciences, Inc. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- Assembly Biosciences, Inc. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- Assembly Biosciences, Inc. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
- Assembly Biosciences, Inc. deferred income tax expense (benefit) for fiscal 2021 was -$2.53M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 6 month as first filed | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 9 month as first filed | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-20 | ||||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 | ||||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 | ||||||
| 2021-12-31 | -$2.53M 10-K · filed 2023-03-22 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 derived: sum of 3 quarters · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | -$741.00K derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | -$741.00K derived: sum of 3 quarters · filed 2021-02-25 | -$756.00K derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-08 | -$741.00K derived: sum of 2 quarters · filed 2021-02-25 | -$756.00K derived: sum of 3 quarters · filed 2021-02-25 | -$767.00K derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-12-31 | -$741.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$756.00K derived: sum of 2 quarters · filed 2021-02-25 | -$767.00K derived: sum of 3 quarters · filed 2021-02-25 | -$774.00K 10-K · filed 2021-02-25 | |||
| 2019-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$26.00K derived: sum of 2 quarters · filed 2020-11-05 | -$33.00K 10-Q · filed 2020-11-05 | -$10.00K 10-Q · filed 2019-11-07 | $1.11M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$18.00K 10-Q · filed 2020-08-05 | $1.12M derived: sum of 3 quarters · filed 2021-02-25 | $1.11M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | -$7.00K 10-Q · filed 2020-05-08 | $1.13M derived: sum of 2 quarters · filed 2021-02-25 | $1.13M derived: sum of 3 quarters · filed 2021-02-25 | $1.09M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.13M derived: sum of 2 quarters · filed 2021-02-25 | $1.10M derived: sum of 3 quarters · filed 2021-02-25 | $1.10M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$40.00K derived: sum of 2 quarters · filed 2019-11-07 | -$40.00K 10-Q · filed 2019-11-07 | -$40.45K 10-Q · filed 2018-11-08 | -$8.98M derived: sum of 4 quarters · filed 2020-03-04 | ||
| 2018-06-30 | -$34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$34.00K 10-Q · filed 2019-08-05 | -$33.91K 10-Q · filed 2018-08-08 | -$8.98M derived: sum of 3 quarters · filed 2020-03-04 | -$9.01M derived: sum of 4 quarters · filed 2020-03-04 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | -$8.94M derived: sum of 2 quarters · filed 2020-03-04 | -$8.98M derived: sum of 3 quarters · filed 2020-03-04 | ||||
| 2017-12-31 | -$8.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | -$8.98M derived: sum of 2 quarters · filed 2020-03-04 | -$9.05M 10-K · filed 2020-03-04 | -$9.05M 10-K · filed 2018-03-08 | |||
| 2017-09-30 | -$35.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$105.42K 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | -$69.51K 10-Q · filed 2018-08-08 | ||||||
| 2016-12-31 | -$618.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$618.00K derived: sum of 2 quarters · filed 2019-02-28 | -$618.00K 10-K · filed 2019-02-28 | -$617.67K 10-K · filed 2017-03-02 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | |||||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | ||||||
| 2015-12-31 | $0.00 10-K · filed 2018-03-08 | ||||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |